Despite the emerging of RAS blockades, SGLT2 inhibitors and NS-MRAs, current treatment options are limited in their ability to effectively impede kidney disease progression and abate risks of comorbidities and death among patients with DKD. The gene discussed is SLC5A2; the disease is kidney disorder.